Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMMONIUM CHLORIDE IN PLASTIC CONTAINER vs GUAIFENESIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.
Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.
Treatment of metabolic alkalosis,Urinary acidification to facilitate excretion of weak bases in poisoning,Hypochloremic states
Relief of productive cough associated with respiratory tract infections and common cold,Off-label: use as a muscle relaxant (unproven)
For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.
Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.
Terminal elimination half-life is approximately 2-4 hours in adults with normal hepatic and renal function. This reflects the rapid conversion of ammonium to urea in the liver and subsequent renal clearance. Half-life may be prolonged in hepatic or renal impairment.
Terminal elimination half-life: 3-5 hours; clinical context: requires dosing every 4-6 hours for sustained mucolytic effect
Metabolized primarily in the liver via the urea cycle; ammonium ion is converted to urea, releasing hydrogen ions. The chloride ion is excreted renally.
Primarily hepatic via oxidation and demethylation; major metabolite is beta-(2-methoxyphenoxy)lactic acid. CYP450 enzymes not significantly involved.
Renal: >99% as ammonium and chloride ions. The kidney converts ammonia to urea, which is excreted in urine. Fecal and biliary elimination are negligible.
Renal: ~95% (primarily as unchanged drug and glucuronide conjugate); biliary/fecal: minimal (<5%)
<1% bound to plasma proteins. Ammonium ions are primarily free in plasma.
~50% (bound to albumin)
Approximately 0.2-0.3 L/kg, reflecting distribution mainly in extracellular fluid. Ammonium ions do not significantly penetrate cells under normal conditions.
~1 L/kg; clinical meaning: extensive distribution into extravascular tissues, including respiratory secretions
Oral: ~100% absorbed from the gastrointestinal tract, though first-pass hepatic metabolism (urea cycle) limits systemic availability of intact ammonium. Intravenous: 100% bioavailable.
Oral: 80-85% (first-pass metabolism minimal)
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-50 m L/min: reduce dose by 50% and monitor serum chloride and ammonia. For GFR >50 m L/min: no adjustment necessary.
No specific guidelines; use caution in severe impairment due to potential accumulation of metabolites.
Contraindicated in severe hepatic insufficiency (Child-Pugh class C). For Child-Pugh class B: use with caution, reduce dose by 50% and monitor ammonia levels. For Child-Pugh class A: no adjustment necessary.
No adjustment required for mild to moderate impairment; insufficient data for severe impairment.
For metabolic alkalosis: 50-100 mg/kg intravenously every 6-8 hours; maximum 2 g/day. For hypochloremic states: 75 mg/kg/day orally in divided doses.
Children 2-5 years: 50-100 mg every 4 hours, max 600 mg/day; 6-11 years: 100-200 mg every 4 hours, max 1200 mg/day; ≥12 years: same as adult.
Start at lower end of dosing range (e.g., 1 g intravenously every 12 hours) due to age-related decline in renal function; monitor serum electrolytes and renal function closely.
No specific adjustment; use lowest effective dose due to increased sensitivity and risk of adverse effects.
None
None
Use with caution in patients with hepatic impairment (risk of ammonia toxicity), renal dysfunction, or respiratory acidosis. Monitor acid-base status, serum chloride, and ammonia levels. Avoid rapid infusion to prevent severe acidosis. Not for use in severe hepatic insufficiency.
Use with caution in patients with persistent or chronic cough (e.g., smoking, asthma, COPD); if cough persists >7 days or recurs, or with fever/rash/headache, discontinue and evaluate.
Severe hepatic insufficiency; severe renal failure with oliguria or anuria; primary respiratory acidosis; hypokalemia (due to risk of exacerbating potassium loss); hypersensitivity to ammonium chloride.
Hypersensitivity to guaifenesin or any component of the formulation.
Avoid excessive dietary intake of chloride-rich foods (e.g., table salt, processed foods) as it may affect treatment. No specific food restrictions, but maintain balanced diet as advised by physician.
No significant food interactions. Alcohol may exacerbate CNS depressant effects.
FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if maternal acidosis induced. Second/third trimester: may cause fetal acidosis, electrolyte disturbances, and potential for fetal harm if maternal overdose or pre-existing acidosis.
Insufficient human data; animal studies show no evidence of fetal harm. Generally considered low risk across all trimesters, though use in first trimester should be cautious due to lack of robust data.
No human data on excretion in breast milk. M/P ratio unknown. Caution advised; consider risk of infant acidosis and ammonia toxicity if exposed.
Excretion into breast milk is likely minimal; M/P ratio not established. AAP considers compatible with breastfeeding; avoid excessive doses.
No established dose adjustment for pregnancy. Decreased GI motility and increased plasma volume may alter absorption and distribution; however, dosing should be guided by clinical response and frequent monitoring of acid-base and electrolyte status. Avoid overdosing to prevent maternal and fetal acidosis.
No dosage adjustment necessary. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) are not clinically significant for guaifenesin.
Ammonium chloride is used to treat severe metabolic alkalosis by providing chloride ions and generating mild metabolic acidosis. Monitor serum chloride, bicarbonate, and p H closely during infusion. Avoid in patients with severe hepatic impairment or renal failure. Infusion may cause local irritation; ensure proper IV access.
Guaifenesin is an expectorant that increases respiratory tract fluid to reduce mucus viscosity. Onset of action is about 30 minutes; duration is 4-6 hours. Maximum effect requires adequate hydration. Avoid in persistent cough due to smoking, asthma, or emphysema. Use caution in renal impairment (Cr Cl <30 m L/min). Not recommended for children under 6 years without medical advice.
This medication is used to correct an acid-base imbalance in your blood.,It will be given intravenously (IV) by a healthcare professional.,Report any burning, pain, or redness at the IV site immediately.,Do not consume large amounts of salt or salty foods unless directed.,Tell your doctor if you have liver or kidney disease.
Drink plenty of water while taking this medication to help loosen mucus.,Do not take for more than 7 days unless directed by a doctor.,Stop use and consult a doctor if cough persists for more than 7 days, is accompanied by fever, rash, or persistent headache.,Avoid alcohol as it may increase dizziness or drowsiness.,Do not crush or chew extended-release tablets; swallow whole.
"Ammonium chloride, an acidifying agent, reduces urinary pH, which increases the renal clearance of lisdexamfetamine and its active metabolite d-amphetamine. This accelerated elimination leads to decreased systemic exposure and potentially diminished therapeutic efficacy of lisdexamfetamine. Clinically, patients may experience reduced symptom control for ADHD or binge eating disorder, requiring dose adjustments or alternative therapies."
"Sufentanil, a potent opioid analgesic, may increase renal excretion of ammonium chloride by promoting diuresis through opioid-induced release of antidiuretic hormone (ADH) and subsequent water reabsorption, leading to dilutional acidosis and enhanced ammonium excretion. This interaction can result in reduced serum ammonium levels and decreased efficacy of ammonium chloride as an acidifying agent, potentially compromising its therapeutic effect in metabolic alkalosis or urinary tract infections. Clinical outcomes may include incomplete correction of metabolic alkalosis or reduced antimicrobial activity of ammonium chloride in the urine."
"Ammonium chloride acidifies the urine, which increases the renal excretion of amphetamine by favoring its ionized form in the tubular lumen, thereby reducing its reabsorption. This leads to a decreased serum concentration of amphetamine and potentially diminished therapeutic efficacy. Clinically, patients may experience reduced mood-elevating or stimulant effects, requiring dose adjustment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMMONIUM CHLORIDE IN PLASTIC CONTAINER vs GUAIFENESIN, answered by our medical review team.
AMMONIUM CHLORIDE IN PLASTIC CONTAINER is a Expectorant/Systemic Acidifier that works by Ammonium chloride is an acidifying agent that provides chloride ions and ammonium ions. The ammonium ion is converted to urea in the liver, releasing hydrogen ions, which leads to metabolic acidosis. It also directly stimulates the respiratory center and promotes diuresis by increasing the osmotic load.. GUAIFENESIN is a Expectorant that works by Guaifenesin is an expectorant that increases respiratory tract fluid secretion and reduces mucus viscosity, facilitating expectoration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMMONIUM CHLORIDE IN PLASTIC CONTAINER and GUAIFENESIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMMONIUM CHLORIDE IN PLASTIC CONTAINER is: For metabolic alkalosis: 1-2 g intravenously every 6-12 hours as needed; maximum 6 g/day. For hypochloremic states: 1-2 g orally or intravenously 2-3 times daily.. The standard adult dose of GUAIFENESIN is: Oral: 200-400 mg every 4 hours as needed, not to exceed 2400 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMMONIUM CHLORIDE IN PLASTIC CONTAINER and GUAIFENESIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMMONIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category C. FDA Pregnancy Category C. Ammonium chloride crosses the placenta. First trimester: insufficient human data; animal studies not available; theoretical risk of fetal acidosis if mate. GUAIFENESIN is classified as Category C. Insufficient human data; animal studies show no evidence of fetal harm. Generally considered low risk across all trimesters, though use in first trimester should be cautious due to. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.